Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Stopped early · Phase 1

Conditions studied: Acute Myeloid Leukemia

In brief

The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Key facts

Study ID

NCT04789408

Run by

Kite, A Gilead Company

People needed

15

Starts

2021-07-19

Expected to finish

2024-05-18

Last updated by the study team

2025-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford Cancer Center — Stanford, California, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• The Ohio State University Wexner Medical Center/James Cancer Hospital — Columbus, Ohio, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Fred Hutchinson Cancer Center — Seattle, Washington, United States
• Institut Paoli-Calmettes — Marseille, France
• CHU de Toulouse Institut Universitaire du Cancer Toulouse Oncopole — Toulouse, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.